Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM)

Diabetes Care

Volumn 21, Issue 4, 1998, Pages 574-579

  Abraira, Carlos ^a,f   Henderson, William G ^a   Colwell, John A ^b   Nuttall, Frank Q ^c   Comstock, John P ^d   Emanuele, Nicholas V ^a   Levin, Seymour R ^e   Sawin, Clark T ^e   Silbert, Cynthia K ^e  

^a DVA Cooperative Studies Center   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c VA MEDICAL CENTER   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIPIZIDE; HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HOME MONITORING; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FASTING; GLIPIZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0031921748     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.4.574     Document Type: Article

References (19)

1. Abraira C, Emanuele N, Colwell J, Henderson WG, Levin S, Nuttall F, Sawin C, Silbert C, Lee HS, Nagel NJ, the VA CSDM Study Group: Glycemic control and complications in type 2 diabetes: design of a feasibility trial. Diabetes Care 7:1079-1102, 1992
2. Abraira C, Colwell JA, Nuttall F, Sawin C, Johnson-Nagel N, Comstock J, Emanuele N, Levin S, Henderson W, Lee HS: VA Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes: results of the feasibility trial. Diabetes Care 18:1113-1123, 1995
3. Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, Levin S, Nuttall F, Sawin C, Silbert C, Lee HS, Nagel NJ, the VA CSDM Study Group: Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes (VA CSDM). Diabetes Care 19:1375-1381, 1996
4. Abraira C, Colwell J, Nuttall F, Sawin C, Henderson W, Comstock J, Emanuele N, Levin S, Pacold I, Lee MS, VA CSDM Group: Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Int Med 157:181-188, 1997
5. Stenman S, Melander A, Groop PH, Groop LC: What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118:169-172, 1993
6. Whalin-Boll E, Sartor G, Melander A: Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharm 22:21-25, 1982
7. Groop LC, Ratheiser K, Luzi L, Melander A, Simonson D, Petrides A: Effect of sulfonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose response study. Acta Diabetol 28:162-168, 1991
8. American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDDM (Consensus Statement). Diabetes Care 19 (Suppl. 1):554-561, 1996
9. Bloomgarden ZT: American Diabetes Association Postgraduate Course 1996: treatment and prevention of diabetes. Diabetes Care 19:784-786, 1996
10. Eastman RC, Gorden P: The DCCT: implications for diabetes treatment. Diabetes Rev 2:263-271, 1994
11. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
12. Raskin P: Combination therapy in NIDDM. N Engl J Med 327:1453-1454, 1992
13. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala T, Tulokas T, Vilkari J, Karjalainen J, Taskinen MR: Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. N Engl Med 327:1426-1433, 1993
14. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Study 13: relative efficacy of randomly allocated diet, sulfonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
15. Soneru I, Agrawal L, Murphy J, Lawrence AM, Abraira C: Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure. Diabetes Care 16:896-901, 1993
16. Garg SK, Carmain JA, Braddy KC, Anderson H, Vignati L, Jennings MK, Chase HP: Pre-meal insulin analogue insulin lispro or humulin insulin treatment in young subjects with type I diabetes. Diabet Med 13:47-52, 1996
17. Schade DS: Commentary. Diabetes Spectrum 9:239-240, 1996
18. Genuth S: Insulin use in NIDDM. Diabetes Care 13:1240-1264, 1990
19. Ohkubo Y, Kishikawa M, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichizi M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diab Res Clin Pract 28:103-117, 1995